Antagonism of P2Y12 reduces physiological thromboxane levels

Platelets

Volumn 21, Issue 8, 2010, Pages 604-609

  Bhavaraju, Kamala ^a,b   Georgakis, Alexander ^b   Jin, Jianguo ^a,b   Kent Gartner, Theodore ^c   Tomiyama, Yoshiaki ^d,e   Nurden, Alan ^f   Nurden, Paquita ^f   Kunapuli, Satya P ^a,b  

^a TEMPLE UNIVERSITY   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MEMPHIS   (United States)

^d OSAKA UNIVERSITY   (Japan)

^e KYOTO SECOND RED CROSS HOSPITAL   (Japan)

^f Ctr Geriatrie Ctr Hosp Univ B   (France)

Author keywords

adenosine diphosphate (ADP); aspirin; coronary artery disease; P2Y12 antagonists; protease activated receptors (PARs); Serum thromboxane

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DRUG METABOLITE; EFFIENT; PRASUGREL; PROTEINASE ACTIVATED RECEPTOR; PURINERGIC P2Y1 RECEPTOR; PURINERGIC P2Y12 RECEPTOR; PURINERGIC RECEPTOR BLOCKING AGENT; R 138727; R 361015; THROMBOXANE; THROMBOXANE A2; THROMBOXANE B2; UNCLASSIFIED DRUG; DRUG DERIVATIVE; PIPERAZINE DERIVATIVE; PURINERGIC P2Y RECEPTOR ANTAGONIST; THIOPHENE DERIVATIVE; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ADULT; ANIMAL EXPERIMENT; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG CONTRAINDICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; LOADING DRUG DOSE; MOUSE; NONHUMAN; NORMAL HUMAN; PILOT STUDY; PRIORITY JOURNAL; SERUM; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS; ADOLESCENT; ANIMAL; BLOOD; CLINICAL TRIAL; DRUG EFFECT; FEMALE; GENETICS; MALE; METABOLISM; MIDDLE AGED; MOUSE MUTANT; THROMBOCYTE;

MUS;

ADENOSINE DIPHOSPHATE; ADOLESCENT; ADULT; ANIMALS; BLOOD PLATELETS; FEMALE; HUMANS; MALE; MICE; MICE, KNOCKOUT; MIDDLE AGED; PILOT PROJECTS; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2Y12; THIOPHENES; THROMBOXANES; TICLOPIDINE; YOUNG ADULT;

EID: 78149454375     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.3109/09537104.2010.511684     Document Type: Article

References (36)

1. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, Ford E, Furie K, Go A, Greenlund K, et al. Heart disease and stroke statistics-2009 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008;119: e21-181. (Pubitemid 43754289)
2. Nieswandt B, Watson SP. Platelet-collagen interaction: Is GPVI the central receptor? Blood 2003;102:449-461. (Pubitemid 36841960)
3. Kahn ML, Nakanishi-Matsui M, Shapiro MJ, Ishihara H, Coughlin SR. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest 1999;103:879-887. (Pubitemid 29152634)
4. Kahner BN, Shankar H, Murugappan S, Prasad GL, Kunapuli SP. Nucleotide receptor signaling in platelets. J Thromb Haemost 2006;4:2317-2326. (Pubitemid 44575423)
5. Paul BZ, Jin J, Kunapuli SP. Molecular mechanism of thromboxane A(2)-induced platelet aggregation. Essential role for p2t(ac) and alpha(2a) receptors. J Biol Chem 1999;274:29108-29114. (Pubitemid 129625641)
6. Ruggeri ZM. Mechanisms initiating platelet thrombus forma-tion. Thromb Haemost 1997;78:611-616.
7. Willoughby S, Holmes A, Loscalzo J. Platelets and cardio-vascular disease. Eur J Cardiovasc Nurs 2002;1:273-288.
8. Kunapuli SP. P2 receptors and platelet activation. Scientific World Journal 2002;2:424-433.
9. Kamae T, Shiraga M, Kashiwagi H, Kato H, Tadokoro S, Kurata Y, et al. Critical role of ADP interaction with P2Y12 receptor in the maintenance of alpha(IIb)beta3 activation: Association with Rap1B activation. J Thromb Haemost 2006;4:1379-1387.
10. Andre P, Delaney SM, LaRocca T, Vincent D, DeGuzman F, Jurek M, et al. P2Y12 regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries. J Clin Invest 2003;112:398-406. (Pubitemid 38063768)
11. Dorsam RT, Kunapuli SP. Central roleof the P2Y12 receptor in platelet activation. J Clin Invest 2004;113:340-345.
12. Grove EL, Storey RF. The right oral antithrombotics in acute coronary syndromes. Lancet 2009;374:1947-1948.
13. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopido-grel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-1057.
14. Patrono C, Rocca B. Aspirin, 110 years later. J Thromb Haemost 2009;7(Suppl 1):258-261.
15. Smyth SS, Woulfe DS, Weitz JI, Gachet C, Conley PB, Goodman SG, Roe MT, Kuliopulos A, Moliterno DJ, French PA, et al. G-protein-coupled receptors as signaling targets for antiplatelet therapy. Arterioscler Thromb Vasc Biol 2009; 29:449-457.
16. Cattaneo M. Laboratory detection of 'aspirin resistance': What test should we use (if any)? Eur Heart J 2007;28: 1673-1675. (Pubitemid 47227105)
17. Tantry US, Mahla E, Gurbel PA. Aspirin resistance. Prog Cardiovasc Dis 2009;52:141-152.
18. Bjorklund L, Wallander MA, Johansson S, Lesen E. Aspirin in cardiology-benefits and risks. Int J Clin Pract 2009;63: 468-477.
19. Reilly IA, FitzGerald GA. Inhibition ofthromboxane forma-tion in vivo and ex vivo: Implications for therapy with platelet inhibitorydrugs. Blood 1987;69:180-186.
20. Kim S, Jin J, Kunapuli SP. Akt activation in platelets depends on Gi signaling pathways. J Biol Chem 2004;279: 4186-4195. (Pubitemid 38199005)
21. Foster CJ, Prosser DM, Agans JM, Zhai Y, Smith MD, Lachowicz JE, et al. Molecular identification and character-ization of the platelet ADP receptor targeted by thienopyr-idine antithrombotic drugs. J Clin Invest 2001;107: 1591-1598. (Pubitemid 32574645)
22. Shiraga M, Miyata S, Kato H, Kashiwagi H, Honda S, Kurata Y, et al. Impaired platelet function in a patient with P2Y12 deficiency caused by a mutation in the translation initiation codon. J Thromb Haemost 2005;3:2315-2323. (Pubitemid 41727212)
23. Nurden P, Savi P, Heilmann E, Bihour C, Herbert JM, Maffrand JP, et al. An inherited bleeding disorder linked to a defective interaction between ADP and its receptor on platelets. Its influence on glycoprotein IIb-IIIa complex function. J Clin Invest 1995;95:1612-1622.
24. Bhavaraju K, Kim S, Daniel JL, Kunapuli SP. Evaluation of [3-(1-methyl-1H-indol-3-yl-methylene)-2-oxo-2, 3-dihydro-1H-indole-5- sulfonamide] (OXSI-2), as a Syk-selective inhibitor inplatelets. EurJPharmacol 2008;580:285-290.
25. Mitchell MD, Bibby JG, Hicks BR, Redman CW, Anderson AB, Turnbull AC Thromboxane B2 and human parturition: Concentrations in the plasma and production in vitro. JEndocrinol 1978;78:435-441.
26. Hashimoto M, Sugidachi A, Isobe T, Niitsu Y, Ogawa T, Jakubowski JA, et al. The influence of P2Y12 receptor deficiency on the platelet inhibitory activities of prasugrel in a mouse model: Evidence for specific inhibition of P2Y12 receptors by prasugrel. Biochem Pharmacol 2007;74: 1003-1009. (Pubitemid 47284007)
27. Alessandrini P, Avogaro P, Bittolo Bon G, Patrignani P, Patrono C. Physiologic variables affecting thromboxane B2 production in human whole blood. Thromb Res 1985;37:1-8. (Pubitemid 15163069)
28. Carter AJ, Hanley SP. The effect of platelet number and haematocrit on whole blood thromboxane synthesis. Thromb Haemost 1985;53:225-227. (Pubitemid 15052702)
29. Cattaneo M, Lecchi A, Lombardi R, Gachet C, Zighetti ML. Platelets from a patient heterozygous for the defect of P2CYC receptors for ADP have a secretion defect despite normal thromboxane A2 pro-duction and normal granule stores: Further evidence that some cases of platelet 'primary secretion defect' are heterozygous for a defect of P2CYC receptors. Arterioscler Thromb Vasc Biol 2000;20:E101-106.
30. Hollopeter G, Jantzen HM, Vincent D, Li G, England L, Ramakrishnan V, et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001;409:202-207. (Pubitemid 32144286)
31. Andre P, DeGuzman F, Mills S, Pak Y, Inagaki M, Pandey A, Hollenbach S, Phillip D, Conley P. Clopidogrel and prasugrel prolong primary hemostasis in the mouse beyond levels associated with P2Y12 inhibition. JTH 2009;7(Supplement 2)AS-TH-022.
32. van der Meijden PE, Feijge MA, Giesen PL, Huijberts M, van Raak LP, Heemskerk JW. Platelet P2Y12 receptors enhance signalling towards procoagu-lant activity and thrombin generation. A study with healthy subjects and patients at thrombotic risk. Thromb Haemost 2005;93:1128-1136. (Pubitemid 40823519)
33. Jin J, Quinton TM, Zhang J, Rittenhouse SE, Kunapuli SP. Adenosine diphosphate (ADP)-induced thromboxane A(2) generation in human platelets requires coordinated signaling through integrin alpha(IIb)beta(3) and ADP receptors. Blood 2002;99:193-198.
34. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996;348: 1329-1339.
35. Armstrong PC, Dhanji AR, Tucker AT, Mitchell JA, Warner TD. Reduction of platelet thromboxane A2 production ex vivo and in vivo by clopidogrel therapy. J Thromb Haemost 2009;8:613-615.
36. Bhatt DL, Marso SP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol 2002;90:625-628. (Pubitemid 35264538)